Disc Medicine, Inc. (NASDAQ:IRON) Given Average Rating of “Moderate Buy” by Analysts

Shares of Disc Medicine, Inc. (NASDAQ:IRON) have been assigned an average recommendation of “Moderate Buy” from the twelve research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $105.30.

A number of equities analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Disc Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a research note on Monday, April 20th. Stifel Nicolaus dropped their price objective on shares of Disc Medicine from $125.00 to $110.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. Wells Fargo & Company increased their price objective on shares of Disc Medicine from $78.00 to $79.00 and gave the company an “overweight” rating in a research note on Monday, March 2nd. Finally, Morgan Stanley increased their price objective on shares of Disc Medicine from $75.00 to $80.00 and gave the company an “overweight” rating in a research note on Thursday, May 14th.

Insider Buying and Selling

In other Disc Medicine news, insider William Jacob Savage sold 7,378 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $65.88, for a total value of $486,062.64. Following the completion of the sale, the insider directly owned 85,211 shares in the company, valued at $5,613,700.68. This trade represents a 7.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Jean M. Franchi sold 6,257 shares of the firm’s stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $69.24, for a total transaction of $433,234.68. Following the completion of the sale, the chief financial officer owned 64,333 shares of the company’s stock, valued at approximately $4,454,416.92. This trade represents a 8.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 20,119 shares of company stock worth $1,351,699. Insiders own 3.76% of the company’s stock.

Institutional Investors Weigh In On Disc Medicine

Institutional investors have recently bought and sold shares of the company. Assenagon Asset Management S.A. boosted its stake in Disc Medicine by 3,329.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 357,836 shares of the company’s stock valued at $28,416,000 after acquiring an additional 347,403 shares in the last quarter. TimesSquare Capital Management LLC acquired a new stake in Disc Medicine in the third quarter valued at approximately $12,038,000. Y Intercept Hong Kong Ltd boosted its stake in Disc Medicine by 361.4% in the third quarter. Y Intercept Hong Kong Ltd now owns 43,287 shares of the company’s stock valued at $2,860,000 after acquiring an additional 33,905 shares in the last quarter. Atle Fund Management AB boosted its stake in Disc Medicine by 85.3% in the third quarter. Atle Fund Management AB now owns 45,690 shares of the company’s stock valued at $3,019,000 after acquiring an additional 21,038 shares in the last quarter. Finally, Hudson Bay Capital Management LP acquired a new stake in Disc Medicine in the third quarter valued at approximately $6,752,000. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Disc Medicine Stock Performance

Shares of NASDAQ:IRON opened at $66.82 on Tuesday. The firm has a market cap of $2.55 billion, a PE ratio of -10.09 and a beta of 0.93. The firm’s 50 day simple moving average is $65.74 and its 200-day simple moving average is $74.56. Disc Medicine has a one year low of $40.00 and a one year high of $99.50. The company has a debt-to-equity ratio of 0.04, a quick ratio of 24.00 and a current ratio of 24.00.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03). As a group, equities analysts predict that Disc Medicine will post -6.78 EPS for the current year.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.